Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?
| Image |  |
|---|---|
| Description | scientific article published in January 2017 |
| Author/s | |
| Publication date | January 1, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |